Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Read full analysis

Key Stats

  • Market Cap
    $23.30B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $118.52
  • 52W Low
    $67.38
  • Typical Hold Time
    -
  • Enterprise Value
    $19.33B
  • Div Yield
    -
  • Trading Activity
    -
$117.96
52W Low: $67.38
21 Jul 2025
52W High: $118.52
09 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.38 and a high of $118.52, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

Unipart, KBR, and IBM launch Team ORION to enhance UK defence logistics and technology resilience

Unipart, KBR, and IBM have formed Team ORION to provide advanced logistics, operational resilience, and cutting-edge technology to the UK Ministry of Defence. This collaboration combines Unipart's supply chain expertise, KBR's defence experience, and...

Market News
22 minutes ago
Na
Bullish
news icon
pluang ai news

Xeriant patents fire-resistant composite; Argo Graphene names new CEO; Aecon wins $815M Winnipeg infrastructure contract.

Xeriant secured a U.S. patent for its fire-resistant composite technology, advancing its eco-friendly construction panel NEXBOARD™ toward commercialization. Argo Graphene Solutions appointed Dr. Vikas Berry, the inventor of its STREAM™ graphene platf...

Market News
32 minutes ago
24/7 Market News
Bullish
news icon
pluang ai news

Allstate's catastrophe losses fall in 2026, but UBS downgrades stock to Neutral amid profit concerns

Allstate reported a 43.7% drop in first-quarter catastrophe losses year-over-year, with Q2 losses also down 14% compared to 2025. Despite improved underwriting results, UBS downgraded Allstate from Buy to Neutral, citing concerns that favorable loss ...

Market News
1 hour ago
Rayan Ahmad
Neutral
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $23.30B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $118.52
  • 52W Low
    $67.38
  • Typical Hold Time
    -
  • Enterprise Value
    $19.33B
  • Div Yield
    -
  • Trading Activity
    -
$117.96
52W Low: $67.38
21 Jul 2025
52W High: $118.52
09 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.38 and a high of $118.52, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!